Group 4A: Metastatic Breast Cancer; ER+; Novel Drugs

Poster #P4-10-28: Efficacy, safety and biomarker results of AC699, a chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer

Poster #P2-07-22: Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced HR+ breast cancer after CDK4/6i: dose escalation data from the Phase 1b/2 SUMIT-ELA study